Portillo Canales presented her research on July 14 at ENDO 2025, the Endocrine Societys annual meeting in San Francisco, California
Updated February 2026 GLP-1 Drugs and Mental Health: What the Evidence Actually Shows The FDA cleared GLP-1 drugs of psychiatric risk after reviewing 91 trials
Notably, after 43 days of treatment, significant reductions in AUC were observed in all groups receiving GLP-1 receptor agonists, indicating improved glycemic control ( Figure S4B , D , Method S3 )
11 trials
The vitamin may play a role in preventing brain atrophy, which is the loss of neurons in the brain and often associated with memory loss or dementia
3 Although no studies have prospectively stratified patients by baseline A1C in evaluation of the A1C-lowering efficacy of a DPP-4 inhibitor or SGLT2 inhibitor, post-hoc subgroup analyses have shown that the efficacy of SGLT2 inhibitors is greater than that of DPP-4 inhibitors among patients with higher baseline A1C ( 8-8.5%), while patients with baseline A1C at the lower end of the spectrum ( 30 mL/min and clinical CV disease according to Diabetes Canada
